Background: The dosage of carboplatin in cats has been reported anecdotally and experimentally in non-tumor-bearing cats, but the dosage for carboplatin treatment in tumor-bearing cats has yet to be defined in a prospective clinical trial.Purpose: To determine the maximally tolerated dose (MTD) and dose-limiting toxicosis (DLT) of carboplatin in tumorbearing cats.Cats: Fifty-nine cats with measurable solid tumors. Methods: The starting dose of carboplatin was 160 mg/m 2 of body surface area IV. Doses were increased by 20 mg/m 2 in cohorts of 3-14 cats until the MTD was reached.Results: The 59 cats entered into this multi-institutional phase I study received 1 or more doses of carboplatin at various dosages and were evaluated for toxicity, response to treatment, or both. The MTD was 240 mg/m 2 and neutropenia was the DLT. For the 1st cycle of treatment in 44 cats evaluated for neutropenia, 6 episodes of grade 3 or greater neutropenia occurred on days 7 (n 5 1), 14 (n 5 4), and 21 (n 5 1). There was no evidence of drug-induced nephrotoxicosis or pulmonary edema. Preliminary evidence of antitumor activity was observed in 7 of 59 (11.9%; 95% CI, 5.6-22.8%) cats evaluated for response to treatment. There was 1 complete response (cutaneous hemangiosarcoma) and 6 partial responses (4 injection site sarcomas, 1 oral squamous cell carcinoma, 1 lymphoma). Responses were of short duration (median, 42 days; range, 7-168 days).Conclusions and Clinical Importance: The dose of carboplatin recommended to treat tumor-bearing cats is 240 mg/m 2 IV every 3-4 weeks.

Background: Adoption of retired racing Greyhounds has become increasingly popular during the past decade. To date, research has focused on the physiologic and clinicopathologic peculiarities of Greyhounds but there is little published information on disease prevalence in the breed.Objective: The objective of this study is to determine the prevalence of disease in retired racing Greyhounds. Animals: In this study, 747 Greyhounds were used. Methods: A standardized survey method was used, and survey responses were collected by an Internet survey. Owners could answer a survey for every Greyhound that they had owned since January 1, 2005.Results: Of the 692 eligible participants, 441 (63.7% response rate) completed surveys for 747 Greyhounds. The mortality rate for Greyhounds within the 2-year period was 15% (113 of 747 died). The most common cause of death reported was cancer (66 dogs, 58%), and the most common type of cancer listed as the cause of death was osteosarcoma (28 dogs, 25%). The most commonly reported groups of diseases or disorders were skeletal (232 dogs, 33%), skin (197 dogs, 28%), digestive (132 dogs, 18%), cancer (94 dogs, 13%), and endocrine (85 dogs, 11.9%). Forty-five percent of Greyhounds diagnosed with cancer and 6% of the overall population had osteosarcoma.Conclusions and Clinical Importance: The results of this study can be used by veterinary researchers to continue to investigate the most common diseases in this population. As more retired racing Greyhounds enter the pet population, the results of this study will help educate veterinarians and owners about the most prevalent diseases in the breed.

Mean decrease in BCS of 2 and mean weight loss of 15% were achieved and maintained in all dogs. An obesity treatment program that included dietary changes and monthly weight checks during the weight loss and weight maintenance periods was sufficient to achieve these results.

Background: Adoption of retired racing Greyhounds has become increasingly popular during the past decade. To date, research has focused on the physiologic and clinicopathologic peculiarities of Greyhounds but there is little published information on disease prevalence in the breed.Objective: The objective of this study is to determine the prevalence of disease in retired racing Greyhounds. Animals: In this study, 747 Greyhounds were used. Methods: A standardized survey method was used, and survey responses were collected by an Internet survey. Owners could answer a survey for every Greyhound that they had owned since January 1, 2005.Results: Of the 692 eligible participants, 441 (63.7% response rate) completed surveys for 747 Greyhounds. The mortality rate for Greyhounds within the 2-year period was 15% (113 of 747 died). The most common cause of death reported was cancer (66 dogs, 58%), and the most common type of cancer listed as the cause of death was osteosarcoma (28 dogs, 25%). The most commonly reported groups of diseases or disorders were skeletal (232 dogs, 33%), skin (197 dogs, 28%), digestive (132 dogs, 18%), cancer (94 dogs, 13%), and endocrine (85 dogs, 11.9%). Forty-five percent of Greyhounds diagnosed with cancer and 6% of the overall population had osteosarcoma.Conclusions and Clinical Importance: The results of this study can be used by veterinary researchers to continue to investigate the most common diseases in this population. As more retired racing Greyhounds enter the pet population, the results of this study will help educate veterinarians and owners about the most prevalent diseases in the breed.